Expression and therapeutic potential of TROP-2 in Cisplatin-resistant non-seminomatous germ cell tumors
Background: Cisplatin-based chemotherapy has been the standard of care for metastatic germ cell tumors (mGCT) for the past four decades due to its high efficacy. However, cisplatin-refractory patients have a poor prognosis due to limited treatment options. Therefore, there is an unmet need for effective [for full text, please go to the a.m. URL]
Institutions
- University Hospital Bonn (DE)
- Klinik und Poliklinik für Urologie (DE)
- Universitätsklinikum Erlangen (DE)
- Institut für Innovative Technologien (Germany) (DE)
- Centrum für Integrierte Onkologie (DE)
- University Hospital Cologne (DE)
- Bundeswehrzentralkrankenhaus Koblenz (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2025-04-02
- DOI
- https://doi.org/10.3205/25nrwgu24
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00